Quantitative Concept
Symbiotic Capital Launches with $600M, Ties to Arie Belldegrun’s Bellco
Symbiotic Capital, Arie Belldegrun, Bellco, $600M, credit firm, biotech, private equity
Bayer Announces 3,200 Job Cuts, Highlights Progress in Pharmaceutical Pipeline
Bayer, job cuts, pharmaceutical pipeline, cost savings, organizational restructuring
23andMe Board Rejects CEO Anne Wojcicki’s Take-Private Plan, Requests Changes
23andMe, Anne Wojcicki, take-private plan, board rejection, financing, stock price, shareholders
Novo Nordisk Faces Setback in IRA Litigation, Vows to Appeal
Novo Nordisk, IRA lawsuit, Medicare price negotiations, legal setback, appeal
Biogen Lifts Outlook as Leqembi Sales Accelerate in Q2
Biogen, Leqembi, Q2 earnings, Alzheimer’s drug, cost cuts, profit outlook
FDA Approves Broader Label for GSK’s Jemperli in First-Line Endometrial Cancer
FDA, GSK, Jemperli, dostarlimab-gxly, endometrial cancer, chemotherapy, carboplatin, paclitaxel, mismatch repair proficient, microsatellite stable, overall survival, progression-free survival
IRA Drug Price Reductions Unlikely to Harm Biotech Innovation, Studies Suggest
Inflation Reduction Act, IRA, drug price negotiations, biotech innovation, Medicare, pharmaceutical industry
Eisai’s Alzheimer’s Drug Leqembi Shows Long-Term Benefits, Despite Study Limitations
Eisai, Leqembi, Alzheimer’s drug, long-term benefits, study limitations, cognitive decline, amyloid plaques, Biogen
Pinetree Therapeutics Secures $17M in Funding to Advance Targeted Protein Degraders
Pinetree Therapeutics, targeted protein degraders, TPD, Series A funding, pharmaceutical development
NICE Rejects AstraZeneca’s Enhertu for Breast Cancer Treatment Due to Pricing Concerns
NICE, AstraZeneca, Enhertu, Breast Cancer, Pricing, Rejection